An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant
- 1 January 2003
- journal article
- case report
- Published by American Society of Hematology in Blood
- Vol. 101 (1), 151-156
- https://doi.org/10.1182/blood-2002-04-1046
Abstract
We describe a von Willebrand disease (VWD) variant characterized by the persistence of von Willebrand factor (VWF) propeptide as a result of a C>T transition at nucleotide 2527 in exon 17 of the VWF gene. This mutation, which was present in the proband and his father, predicts the substitution of Cys for Arg at position 760 of pre–pro-VWF, 4 residues before the propeptide cleavage site belonging to a consensus sequence for substrate recognition by the processing enzyme paired dibasic amino acid–cleaving enzyme (PACE)/furin. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) documented the presence of both processed and unprocessed VWF in the patient's plasma, with unprocessed VWF relatively less represented. The patient's hemostatic phenotype was characterized by a mild decrease in plasma factor VIII (FVIII) and VWF, a decrease in plasma VWF multimers, and a mild reduction in the FVIII binding capacity of VWF. The FVIII binding defect was more pronounced in the proband than in the father because he also inherited the type 2N Arg91Gln mutation from his mother. The persistence of VWF propeptide did not impair VWF synthesis because platelet VWF content was normal, nor did it compromise VWF storage in endothelial cells, because of the normal post–1-deamino-8-D-arginine vasopressin (DDAVP) increase in plasma VWF. Coexpression of wild-type and Arg760Cys VWF into a Furin-producing BHK cell line resulted in decreased VWF secretion and a defect in the FVIII binding capacity of VWF, together with the persistence of VWF propeptide. These findings confirm that a normal consensus sequence for VWF propeptide cleavage and efficient cleavage are required in vivo for normal FVIII binding capacity of VWF.Keywords
This publication has 29 references indexed in Scilit:
- Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co‐factor activity?British Journal of Haematology, 2001
- BIOCHEMISTRY AND GENETICS OF VON WILLEBRAND FACTORAnnual Review of Biochemistry, 1998
- Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand??s disease with low platelet von Willebrand factor contentBlood Coagulation & Fibrinolysis, 1992
- Induction of specific storage organelles by von Willebrand factor propolypeptideCell, 1991
- The propeptide of von Willebrand Factor independently mediates the assembly of von Willebrand multimersCell, 1988
- Identification of disulfide-bridged substructures within human von Willebrand factorBiochemistry, 1987
- Inducible secretion of large, biologically potent von Willebrand factor multimersCell, 1986
- Human von Willebrand Factor (vWF): Isolation of Complementary DNA (cDNA) Clones and Chromosomal LocalizationScience, 1985
- Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.The Journal of cell biology, 1984
- A ‘New’ Congenital Haemorrhagic Condition due to the Presence of an Abnormal Factor X (Factor X Friuli): Study of a Large KindredBritish Journal of Haematology, 1970